What this means
This review looks at how cancer treatments can leave some cells stuck in an aging state that may harm the heart. It does not prove this process causes heart damage, since other factors can also play a part.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- A review of existing studies, not a new experiment
- Kind of research
- A summary of earlier studies
The science
- Original title
- Therapy-induced senescence in breast cancer and cardiovascular disease: a double-edged biological process.
- Authors
- Belcastro E, Fanelli GN, Schiavone ML et al.
- Journal
- Frontiers in cardiovascular medicine
- Published
- Oct 14, 2026
- Study type
- Review
- PMID
- 42871672 ↗
Abstract
Therapy-induced senescence (TIS) has emerged as a central biological response to anticancer therapies, extending beyond tumor suppression to influence long-term tissue homeostasis, cardiovascular (CV) remodeling, and accelerated biological aging. In breast cancer (BC), chemotherapy, radiotherapy, targeted therapies, and emerging immune-activating treatments can induce senescence not only in malignant cells, where it may initially contribute to tumor growth arrest and immune-mediated clearance, but also in non-malignant CV tissues. Persistent accumulation of senescent cells and sustained release of the senescence-associated secretory phenotype (SASP) represent a double-edged sword that may promote chronic inflammation and endothelial dysfunction while contributing to the exacerbation of multifactorial CV outcomes, including myocardial fibrosis, vascular stiffness, and progressive CV dysfunction. Importantly, these outcomes cannot be attributed to TIS alone, as direct therapy-related injury and pre-existing CV risk factors may also contribute. Increasing evidence suggests that TIS-associated mechanisms - including persistent DNA damage response activation, p53/p21- and p16^INK4a^-mediated cell-cycle arrest, NF-κB-driven inflammatory signaling, mitochondrial dysfunction, oxidative stress, and metabolic rewiring - overlap with pathways involved in CV toxicity and systemic tissue remodeling. Through chronic inflammatory and immune-vascular crosstalk, TIS may contribute to a broader phenotype of inflammaging and therapy-associated premature biological aging. Emerging senescence-targeting strategies, including senolytic and senomorphic therapies, represent promising approaches to mitigate long-term CV injury while preserving antitumor efficacy, although their clinical benefit and safety remain to be fully established. This review summarizes current knowledge regarding the dual and systemic role of TIS in BC and CV disease, considering TIS as a candidate, non-exclusive mediator acting alongside direct therapy-related injury, and discusses its translational implications for integrated precision cardio-oncology strategies.
Belcastro E, Fanelli GN, Schiavone ML et al. Therapy-induced senescence in breast cancer and cardiovascular disease: a double-edged biological process. Frontiers in cardiovascular medicine. 2026. doi:10.3389/fcvm.2026.1951892. PMID: 42871672. https://pubmed.ncbi.nlm.nih.gov/42871672/
Related research
A drug pair tested in people with fatty liver disease and scarring
In this small trial, more people on dasatinib plus quercetin had liver scarring improve than those on placebo. The trial was small, and it does not show the drugs are safe or work for everyone.
Old, stuck cells may sometimes help cancer resist treatment
This review looks at how cells that stop dividing after cancer treatment might sometimes help tumors survive. The authors say these cells play a role only in some cases, not in every case.
A tea plant root extract killed aging skin cells in a lab dish
Researchers tested a tea root extract on human skin cells that had been made old in a dish. The extract killed more of the old cells than normal ones, and it also cut some inflammation signals. This does not show the extract works in people, because the tests were done in cells and skin samples.
Cell aging after cancer treatment may help or hurt tumour growth
This paper is a review of earlier research on aged cells and cancer. It says these cells may either slow or speed up tumour growth.
A review of how damaged nerves in the body repair their protective coating
This review gathers what is known about how nerve cells rebuild their coating after injury. It does not test a new treatment, and it suggests future treatments may need to be combined.
Aging immune cells may drive Alzheimer's and Parkinson's, a review says
This review pulls together earlier studies on aging immune cells and brain disease. It suggests these cells may be a target for future treatments, but it does not prove this.
See all research on Senolytics →